Current management and future perspectives of metastatic renal cell carcinoma

International Journal of Urology

Volumn 21, Issue 9, 2014, Pages 847-855

  Lee Ying, Richard ^a   Lester, Renee ^a   Heng, Daniel Y C ^a  

^a TOM BAKER CANCER CENTRE   (Canada)

Author keywords

Immunotherapy; Renal cell cancer; Targeted therapy

Indexed keywords

ANTINEOPLASTIC AGENT; AXITINIB; BEVACIZUMAB; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PAZOPANIB; RECOMBINANT ALPHA INTERFERON; RECOMBINANT INTERLEUKIN 2; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TIVOZANIB; VASCULOTROPIN INHIBITOR;

CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER SURGERY; CANCER SURVIVAL; CYTOREDUCTIVE NEPHRECTOMY; HUMAN; KIDNEY METASTASIS; METASTASIS RESECTION; NEPHRECTOMY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; CARCINOMA, RENAL CELL; FORECASTING; KIDNEY NEOPLASMS; PATHOLOGY; SECONDARY;

CARCINOMA, RENAL CELL; FORECASTING; HUMANS; KIDNEY NEOPLASMS;

EID: 84906669898     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/iju.12502     Document Type: Review

References (82)

1. Gupta K, Miller JD, Li JZ, Russell MW, Charbonneau C. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treat. Rev. 2008; 34: 193-205.
2. Motzer RJ, Agarwal N, Beard C etal. Kidney cancer. J. Natl. Compr. Canc. Netw. 2011; 9: 960-977.
3. Motzer RJ, Russo P. Systemic therapy for renal cell carcinoma. J. Urol. 2000; 163: 408-417.
4. Yang JC, Topalian SL, Parkinson D etal. Randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma: an interim report. J. Clin. Oncol. 1994; 12: 1572-1576.
5. Escudier B, Eisen T, Porta C etal. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2012; 23 (Suppl 7): vii65-71.
6. Fujioka T, Obara W. Committee for Establishment of the Clinical Practice Guideline for the Management of Renal Cell Carcinoma and the Japanese Urological Association. Evidence-based clinical practice guideline for renal cell carcinoma: the Japanese Urological Association 2011 update. Int. J. Urol. 2012; 19: 496-503.
7. Ljungberg B, Bensalah K, Bex A etal. European Urological Association Guidelines on renal cell carcinoma: the 2013 update. 2013. [Cited 23 Jan 2014.] Available from URL: http://www.uroweb.org/gls/pdf/10_Renal_Cell_Carcinoma_LR.pdf
8. Rini BI, Small EJ. Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J. Clin. Oncol. 2005; 23: 1028-1043.
9. Latif F, Duh FM, Gnarra J etal. von Hippel-Lindau syndrome: cloning and identification of the plasma membrane Ca(++)-transporting ATPase isoform 2 gene that resides in the von Hippel-Lindau gene region. Cancer Res. 1993; 53: 861-867.
10. Lin F, Zhang PL, Yang XJ, Prichard JW, Lun M, Brown RE. Morphoproteomic and molecular concomitants of an overexpressed and activated mTOR pathway in renal cell carcinomas. Ann. Clin. Lab. Sci. 2006; 36: 283-293.
11. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J. Clin. Oncol. 1999; 17: 2530-2540.
12. Heng DY, Xie W, Regan MM etal. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J. Clin. Oncol. 2009; 27: 5794-5799.
13. Heng DY, Xie W, Regan MM etal. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol. 2013; 14: 141-148.
14. Kroeger N, Xie W, Lee JL etal. Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents: characterization of survival outcome and application of the International mRCC Database Consortium criteria. Cancer 2013; 119: 2999-3006.
15. Ko J, Wanling X, Heng DY etal. The international metastatic renal cell carcinoma database consortium (IMDC) model as a prognostic tool in metastatic renal cell carcinoma (mRCC) patients previously treated with first-line targeted therapy (TT). J. Clin. Oncol. 2014; 32 (Suppl 5): Abstr 398.
16. McKay RR, Kroeger N, Xie W etal. Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy. Eur. Urol. 2014; 65: 577-584.
17. Smith AD, Shah SN, Rini BI, Lieber ML, Remer EM. Morphology, Attenuation, Size, and Structure (MASS) criteria: assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy. AJR Am. J. Roentgenol. 2010; 194: 1470-1478.
18. Negrier S, Perol D, Ravaud A etal. Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial. Cancer 2007; 110: 2468-2477.
19. Klapper JA, Downey SG, Smith FO etal. High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma: a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006. Cancer 2008; 113: 293-301.
20. Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J. Clin. Oncol. 1995; 13: 688-696.
21. McDermott DF, Regan MM, Clark JI etal. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 2005; 23: 133-141.
22. Coppin C, Porzsolt F, Awa A, Kumpf J, Coldman A, Wilt T. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst. Rev. 2005; (1): CD001425.
23. Motzer RJ, Hutson TE, Tomczak P etal. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 2009; 27: 3584-3590.
24. Sternberg CN, Davis ID, Mardiak J etal. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J. Clin. Oncol. 2010; 28: 1061-1068.
25. Motzer RJ, Hutson TE, Cella D etal. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N. Engl. J. Med. 2013; 369: 722-731.
26. Escudier B, Szczylik C, Hutson TE etal. Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 2009; 27: 1280-1289.
27. Escudier B, Eisen T, Stadler WM etal. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J. Clin. Oncol. 2009; 27: 3312-3318.
28. Hutson TE, Lesovoy V, Al-Shukri S etal. Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial. Lancet Oncol. 2013; 14: 1287-1294.
29. Rini BI, Escudier B, Tomczak P etal. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 2011; 378: 1931-1939.
30. Motzer RJ, Escudier B, Tomczak P etal. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol. 2013; 14: 552-562.
31. Escudier B, Pluzanska A, Koralewski P etal. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007; 370: 2103-2111.
32. Rini BI, Halabi S, Rosenberg JE etal. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J. Clin. Oncol. 2008; 26: 5422-5428.
33. Escudier B, Bellmunt J, Negrier S etal. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J. Clin. Oncol. 2010; 28: 2144-2150.
34. Rini BI, Halabi S, Rosenberg JE etal. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J. Clin. Oncol. 2010; 28: 2137-2143.
35. Atkins MB, Hidalgo M, Stadler WM etal. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J. Clin. Oncol. 2004; 22: 909-918.
36. Hudes G, Carducci M, Tomczak P etal. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N. Engl. J. Med. 2007; 356: 2271-2281.
37. Motzer RJ, Escudier B, Oudard S etal. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008; 372: 449-456.
38. Al-Marrawi MY, Rini BI, Harshman LC etal. The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patients. Target Oncol. 2013; 8: 203-209.
39. Motzer RJ, Barrios CH, Kim TM etal. Record-3: phase II randomized trial comparing sequential first-line everolimus (EVE) and second-line sunitinib (SUN) versus first-line SUN and second-line EVE in patients with metastatic renal cell carcinoma (mRCC). J. Clin. Oncol. 2013; 31 (Suppl): abstr 4504.
40. Hutson TE, Escudier B, Esteban E etal. Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 2013; 32: 760-767.
41. Michel MS, Vervenne W, Goebell PJ etal. Switch: a randomized sequential open-label study to evaluate efficacy and safety of sorafenib (so)/sunitinib (su) versus su/so in the treatment of metastatic renal cell cancer (mRCC). J. Clin. Oncol. 2014; 32 (Suppl): abstr 393.
42. NCT01217931 Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy: The START Trial. 2014. [Cited 9 Jan 2014.] Available from URL: http://www.clinicaltrials.gov
43. Motzer RJ, Szczylik C, Vogelzang NJ etal. Phase 3 trial of dovitinib vs sorafenib in patients with metastatic renal cell carcinoma after 1 prior VEGF pathway-targeted and 1 prior mTOR inhibitor therapy. Eur. J. Cancer 2013; 49 (Suppl 2): Abstr 34.
44. Feldman DR, Baum MS, Ginsberg MS etal. Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 2009; 27: 1432-1439.
45. Molina AM, Feldman DR, Voss MH etal. Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma. Cancer 2012; 118: 1868-1876.
46. Harshman LC, Barbeau S, McMillian A, Srinivas S. A phase II study of bevacizumab and everolimus as treatment for refractory metastatic renal cell carcinoma. Clin. Genitourin. Cancer 2013; 11: 100-106.
47. Negrier S, Gravis G, Perol D etal. Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial. Lancet Oncol. 2011; 12: 673-680.
48. Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R, European Organisation for Research and Treatment of Cancer (EORTC) Genitourinary Group. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 2001; 358: 966-970.
49. Flanigan RC, Salmon SE, Blumenstein BA etal. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N. Engl. J. Med. 2001; 345: 1655-1659.
50. Flanigan RC, Mickisch G, Sylvester R, Tangen C, Van Poppel H, Crawford ED. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J. Urol. 2004; 171: 1071-1076.
51. Heng DY, Rini BI, Beuselinck B etal. Cytoreductive nephrectomy (CN) in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC). J. Clin. Oncol. 2014; 32 (Suppl): Abstr 396.
52. NCT00930033. Clinical Trial to Assess the Importance of Nephrectomy (CARMENA). 2014. [Cited 9 Jan 2014.] Available from URL: http://www.clinicaltrials.gov
53. NCT01099423. Immediate Surgery or Surgery After Sunitinib Malate in Treating Patients With Metastatic Kidney Cancer (SURTIME). 2014. [Cited 9 Jan 2014.] Available from URL: http://www.clinicltrials.gov
54. Kavolius JP, Mastorakos DP, Pavlovich C, Russo P, Burt ME, Brady MS. Resection of metastatic renal cell carcinoma. J. Clin. Oncol. 1998; 16: 2261-2266.
55. Eggener SE, Yossepowitch O, Kundu S, Motzer RJ, Russo P. Risk score and metastasectomy independently impact prognosis of patients with recurrent renal cell carcinoma. J. Urol. 2008; 180: 873-878; discussion 878.
56. Alt AL, Boorjian SA, Lohse CM, Costello BA, Leibovich BC, Blute ML. Survival after complete surgical resection of multiple metastases from renal cell carcinoma. Cancer 2011; 117: 2873-2882.
57. Lin PP, Mirza AN, Lewis VO etal. Patient survival after surgery for osseous metastases from renal cell carcinoma. J. Bone Joint Surg. Am. 2007; 89: 1794-1801.
58. Naito S, Kinoshita H, Kondo T etal. Prognostic factors of patients with metastatic renal cell carcinoma with removed metastases: a multicenter study of 556 patients. Urology 2013; 82: 846-851.
59. Fleischmann JD, Kim B. Interleukin-2 immunotherapy followed by resection of residual renal cell carcinoma. J. Urol. 1991; 145: 938-941.
60. Karam JA, Rini BI, Varella L etal. Metastasectomy after targeted therapy in patients with advanced renal cell carcinoma. J. Urol. 2011; 185: 439-444.
61. NCT01575548. Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery. 2014. [Cited 9 Jan 2014.] Available from URL: http://www.clinicaltrials.gov
62. Hodi FS, O'Day SJ, McDermott DF etal. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 2010; 363: 711-723.
63. Topalian SL, Hodi FS, Brahmer JR etal. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 2012; 366: 2443-2454.
64. Brahmer JR, Tykodi SS, Chow LQ etal. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 2012; 366: 2455-2465.
65. Wolchok JD, Kluger H, Callahan MK etal. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 2013; 369: 122-133.
66. NCT01668784. Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025). 2014. [Cited 9 Jan 2014.] Available from URL: http://www.clinicaltrials.gov
67. NCT01472081. Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016). 2014. [Cited 9 Jan 2014.] Available from URL: http://www.clinicaltrials.gov
68. Cho DC, Sosman JA, Sznol M etal. Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with metastatic renal cell carcinoma (mRCC). J. Clin. Oncol. 2013; 31 (Suppl): abstr 4505.
69. Amin A, Dudek A, Logan TF etal. Prolonged survival with personalized immunotherapy (AGS-003) in combination with sunitinib in unfavorable risk metastatic RCC (mRCC). J. Clin. Oncol. 2013; 31 (Suppl): Abstr 357.
70. NCT01582672: An International Phase 3 Randomized Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (ADAPT). 2014. [Cited 9 Jan 2014.] Available from URL: http://www.clinicaltrials.gov
71. Elisei R, Schlumberger MJ, Muller SP etal. Cabozantinib in progressive medullary thyroid cancer. J. Clin. Oncol. 2013; 31: 3639-3646.
72. Smith DC, Smith MR, Sweeney C etal. Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. J. Clin. Oncol. 2013; 31: 412-419.
73. Choueiri TK, Pal SK, McDermott DF etal. Efficacy of cabozantinib (XL184) in patients with metastatic, refractory renal cell carcinoma. J Clin Oncol, 30. Efficacy of cabozantinib (XL184) in patients with metastatic, refractory renal cell carcinoma. J. Clin. Oncol. 2012; 30 (Suppl): abstr 4504.
74. NCT01865747. A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma (METEOR). 2014. [Cited 9 Jan 2014.] Available from URL: http://www.clinicaltrials.gov
75. Motzer RJ, Nosov D, Eisen T etal. Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial. J. Clin. Oncol. 2013; 31: 3791-3799.
76. Armstrong AJ, George DJ, Halabi S. Serum lactate dehydrogenase predicts for overall survival benefit in patients with metastatic renal cell carcinoma treated with inhibition of mammalian target of rapamycin. J. Clin. Oncol. 2012; 30: 3402-3407.
77. Brugarolas J. PBRM1 and BAP1 as novel targets for renal cell carcinoma. Cancer J. 2013; 19: 324-332.
78. Hakimi AA, Ostrovnaya I, Reva B etal. Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network. Clin. Cancer Res. 2013; 19: 3259-3267.
79. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 2013; 499: 43-49.
80. van der Veldt AA, Eechoute K, Gelderblom H etal. Genetic polymorphisms associated with a prolonged progression-free survival in patients with metastatic renal cell cancer treated with sunitinib. Clin. Cancer Res. 2011; 17: 620-629.
81. Rini BI, Cohen DP, Lu DR etal. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J. Natl. Cancer Inst. 2011; 103: 763-773.
82. Weber JS, Kudchadkar RR, Yu B etal. Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma. J. Clin. Oncol. 2013; 31: 4311-4318.